SEC 13F Intelligence

Tri Locum Partners LP / REGN

Tri Locum Partners LP’s Regeneron Pharmaceuticals Position

Does Tri Locum Partners LP own Regeneron Pharmaceuticals (REGN)? Not currently — the last reported position was 17.5K shares worth $18M in Q2 2024; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$18M
Q2 2024
Shares
17.5K
% of Portfolio
+4.65%
Quarters Held
12
position exited

Position History REGN

Reported value by quarter
Q4 ’20: $5MQ4 ’20Q1 ’21: $31MQ2 ’21: $42MQ2 ’21Q3 ’21: $8MQ1 ’22: $15MQ1 ’22Q3 ’22: $21MQ1 ’23: $36MQ1 ’23Q2 ’23: $15MQ3 ’23: $16MQ3 ’23Q4 ’23: $14MQ1 ’24: $8MQ1 ’24Q2 ’24: $18Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q2 202417.5K$18M+4.65%
Q1 20248.6K$8M+2.86%
Q4 202316.0K$14M+6.43%
Q3 202320.0K$16M+5.27%
Q2 202320.6K$15M+5.51%
Q1 202343.4K$36M+10.86%
Q3 202230.1K$21M+5.69%
Q1 202221.5K$15M+5.86%
Q3 202113.9K$8M+3.35%
Q2 202175.6K$42M+13.83%
Q1 202164.7K$31M+7.59%
Q4 202010.4K$5M+1.83%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Tri Locum Partners LP’s full portfolio or all institutional holders of REGN.